Contents
November 2020
Vol 5, Issue 53
Vol 5, Issue 53
First Release: Perspective
- The known unknowns of T cell immunity to COVID-19
Unanswered questions remain about the contributions of T cell immunity to protective and dysfunctional responses in COVID-19.
Research Articles
- Shiga toxin suppresses noncanonical inflammasome responses to cytosolic LPS
Shiga toxin, a phage-encoded bacterial virulence factor, inhibits caspase-11–mediated inflammasome responses.
- Gut microbiota–specific IgA+ B cells traffic to the CNS in active multiple sclerosis
IgA+ cells act as a systemic mediator between the gut and the central nervous system during active multiple sclerosis.
- Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling
Human common ILC progenitors acquire CD48 and CD52, defining innate lymphoid cell precursors and NK progenitors.
- Type I interferons drive the maturation of human DC3s with a distinct costimulatory profile characterized by high GITRL
Human dendritic cell and monocyte subsets display cell type–specific responses to IFN-I stimulation.
- Cellular context of IL-33 expression dictates impact on anti-helminth immunity
The pore-forming protein perforin-2 facilitates IL-33 release from dendritic cells.
- Tissue-resident CD8+ T cells drive age-associated chronic lung sequelae after viral pneumonia
Age-associated TRM cell malfunction supports chronic lung inflammation and tissue fibrosis after respiratory viral infection.
Review
- T cell factor 1: A master regulator of the T cell response in disease
This review discusses TCF1, which plays context-dependent roles in T cell function during autoimmunity, cancer, and chronic infection.
Editors' Choice
- Torn between type 1 and type 2 immunity
DOCK8 uncovers a link between cell integrity and TH2 skewing.
- Two mAbs take a stab at influenza's NActive site
Two human-derived recombinant mAbs specific for IBV bind the neuraminidase active site by emulating the enzymatic substrate, which results in broad protection.
About The Cover
ONLINE COVER Pneumonia Prophylaxis. This month’s cover depicts intramuscular administration of a vaccine to an elderly man. Lower respiratory virus infections, including influenza and SARS-CoV-2, are more likely to progress to severe pneumonia and a fatal outcome in senior citizens. There is an urgent need for vaccines that show comparable efficacy in seniors and younger individuals. Using a mouse influenza infection model, Goplen et al. found that aged mice sustained more fibrotic lung damage following influenza infection than young mice due to excessive accumulation of dysfunctional tissue-resident memory T cells. [CREDIT: FG TRADE/GETTY IMAGES]
